Shukla Rajiv's Form 4 filing
Longevity Health Holdings, Inc. (XAGE) · filed Nov 21, 2023
- Accession no.
- 0000950170-23-065682
- Filed
- Nov 21, 2023
- Trade date
- Jul 26, 2021-Nov 21, 2023
- Filing delay
- 848 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market purchases total $15.7K. It was filed 848 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shukla RajivCIK 0001709033 | Director, Officer (Chairman and CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 17, 2023 | Common Stock | PPurchaseAcquired | +2,000 | $2.69F1 | +$5,380 | 10,612 | Direct | |
| Nov 20, 2023 | Common Stock | PPurchaseAcquired | +3,750 | $2.62F2 | +$9,825 | 14,362 | Direct | |
| Nov 21, 2023 | Common Stock | PPurchaseAcquired | +200 | $2.49 | +$498 | 14,562 | Direct | |
| Jul 26, 2021 | Common Stock | JOtherAcquired | 0 | $0.00 | $0 | 4,249,908 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $2.60 to $2.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 1.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $2.30 to $2.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2.
Referenced by the price of 1 transaction in Table I.